Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Crizotinib

4

I.a Pneumonitis (ILD), acute and/or severe (may cause ARDS)

2
Last update : 10/01/2020
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
Alk inhibitors
3

Publications

Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer.
ESMO open 2017;2;e000219 2017
Interstitial lung disease arising from erlotinib treatment in a Caucasian patient.
Clinical lung cancer 2015 Mar;16;e1-3 2015 Mar
Crizotinib Associated with Ground-Glass Opacity Predominant Pattern Interstitial Lung Disease: A Retrospective Observational Cohort Study with a Systematic Literature Review.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2015 Aug;10;1148-55 2015 Aug
Managing treatment-related adverse events associated with Alk inhibitors.
Current oncology (Toronto, Ont.) 2014 Feb;21;19-26 2014 Feb
Severe acute interstitial lung disease induced by crizotinib therapy in a patient with c-Met amplification non-small cell lung cancer.
Chinese medical journal 2014;127;1600 2014
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
The New England journal of medicine 2013 Jun 20;368;2385-94 2013 Jun 20
Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013 Jan 01;31;e15-7 2013 Jan 01

Powered by

  • ^
  • Contact
  • Cookies
  • About

The Pneumotox website uses cookies. By accessing or using our website, you consent to the collection, use and disclosure of the garnered information in accordance with our privacy policy.

Learn more about cookies